권호기사보기
기사명 | 저자명 | 페이지 | 원문 | 기사목차 |
---|
대표형(전거형, Authority) | 생물정보 | 이형(異形, Variant) | 소속 | 직위 | 직업 | 활동분야 | 주기 | 서지 | |
---|---|---|---|---|---|---|---|---|---|
연구/단체명을 입력해주세요. |
|
|
|
|
|
* 주제를 선택하시면 검색 상세로 이동합니다.
BACKGROUND/OBJECTIVES: Breast cancer is considered a serious health issue worldwide and is influenced by risk factors, including physical inactivity and unhealthy diet. Myokines secreted by muscles during physical activity play a crucial role in cancer development and the immune system. Genistein (Gen), an isoflavone primarily in legumes, induces anti-cancer activity by regulating cancer stem cells (CSCs). Therefore, this study investigated the potential anti-cancer effect of a combination of myokine and Gen on the human breast cancer MCF-7 cells.
MATERIALS/METHODS: MCF-7, a human breast cancer cell line, was used for in vitro study. The cell viability of MCF-7 cells was evaluated in response to treatment with myokines, irisin (Iri), oncostatin M (OSM), and Gen using the MTT assay. Clonogenic and sphere formation assays were used to evaluate the self-renewal capacity of breast CSCs. The mRNA expression levels of stem cell markers were analyzed in MCF-7 breast cancer cells.
RESULTS: Administering Iri or OSM with Gen significantly inhibited the self-renewal capacity of MCF-7 cells. In addition, mRNA expression of breast CSC markers SOX2 and OCT4, which are characteristic of CSCs, was suppressed by both myokine and Gen. However, combining Iri or OSM with Gen was the most effective treatment.
CONCLUSION: These results suggested that combining Iri or OSM with Gen has an additive effect on breast CSCs by regulating self-renewal capacity and expression of CSCs markers. Therefore, the combination of myokines and Gen may have the therapeutic potential for treating breast cancer and improving the quality of life of cancer patients.
번호 | 참고문헌 | 국회도서관 소장유무 |
---|---|---|
1 | Int J Mol Sci. 2022 Mar 24;23(7): | 미소장 |
2 | Int Immunopharmacol. 2021 Jan;90:107158 | 미소장 |
3 | Breast Cancer Res Treat. 2001 Mar;66(2):111-21 | 미소장 |
4 | Immunol Lett. 2018 Nov;203:1-5 | 미소장 |
5 | Cancer Lett. 2008 Oct 8;269(2):226-42 | 미소장 |
6 | Cancer Epidemiol Biomarkers Prev. 2010 Aug;19(8):1893-907 | 미소장 |
7 | Front Pharmacol. 2022 Jan 24;13:820969 | 미소장 |
8 | Oxid Med Cell Longev. 2021 Jul 19;2021:3268136 | 미소장 |
9 | Curr Drug Metab. 2020;21(1):6-10 | 미소장 |
10 | Stem Cells Int. 2017;2017:5619472 | 미소장 |
11 | Mol Cancer Ther. 2002 Jun;1(8):601-10 | 미소장 |
12 | CA Cancer J Clin. 2023 Jan;73(1):17-48 | 미소장 |
13 | Int Immunopharmacol. 2020 Oct;87:106787 | 미소장 |
14 | Medicine (Baltimore). 2016 Sep;95(1 Suppl 1):S20-S25 | 미소장 |
15 | Clin Exp Metastasis. 2004;21(2):167-76 | 미소장 |
16 | Pharmacol Rep. 2020 Oct;72(5):1125-1151 | 미소장 |
17 | Stem Cell Res Ther. 2013;4(6):146 | 미소장 |
18 | Biochem Soc Trans. 2017 Aug 15;45(4):905-11 | 미소장 |
19 | J Nutr. 2002 Nov;132(11 Suppl):3456S-3464S | 미소장 |
20 | Cureus. 2022 Oct 6;14(10):e30003 | 미소장 |
21 | Am J Physiol Endocrinol Metab. 2011 Sep;301(3):E504-10 | 미소장 |
22 | J Biomed Sci. 2018 Mar 06;25(1):20 | 미소장 |
23 | Nat Protoc. 2006;1(5):2315-9 | 미소장 |
24 | Biochem Biophys Res Commun. 2017 Apr 8;485(3):598-605 | 미소장 |
25 | Lancet Glob Health. 2020 Aug;8(8):e1027-e1037 | 미소장 |
26 | Life Sci. 2020 Mar 15;245:117387 | 미소장 |
27 | Cancer Res. 2010 Jun 1;70(11):4687-97 | 미소장 |
28 | J Tradit Complement Med. 2017 Apr 25;8(2):278-281 | 미소장 |
*표시는 필수 입력사항입니다.
*전화번호 | ※ '-' 없이 휴대폰번호를 입력하세요 |
---|
기사명 | 저자명 | 페이지 | 원문 | 기사목차 |
---|
번호 | 발행일자 | 권호명 | 제본정보 | 자료실 | 원문 | 신청 페이지 |
---|
도서위치안내: / 서가번호:
우편복사 목록담기를 완료하였습니다.
*표시는 필수 입력사항입니다.
저장 되었습니다.